04 December 2017

Ergomed’s PrimeVigilance hosts prestigious intelligent automation seminar for the International Society of Pharmacovigilance

 

 

  • PrimeVigilance hosting Intelligent Automation in Pharmacovigilance seminar in Cambridge, MA, 4-5 December

  • Jan Petracek, CEO of PrimeVigilance, presenting The optimal service mix for 2020

 

London, UK – 4 December 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the ‘Company'), a specialised pharmaceutical services and drug development company, today announces that its pharmacovigilance subsidiary PrimeVigilance will be organising and presenting at the International Society of Pharmacovigilance’s Intelligent Automation in Pharmacovigilance seminar to be held at Biogen’s headquarters in Cambridge, MA, from 4-5 December 2017.

 

Reacting to the question: “can automated processes powered by artificial intelligence provide effective solutions to the ever-increasing challenges in pharmacovigilance?”, this seminar is the first of its kind worldwide to cover this complex development area. Over 30 speakers from the most influential companies in pharmacovigilance automation will present their state of the art technologies and examine the disruption expected within the industry. Participating bodies include: AstraZeneca, Bayer, Biogen, Celgene, Genentech, Takeda and the FDA and the MHRA.

 

PrimeVigilance‘s CEO, Jan Petracek, will be presenting the results from its successful pilot project demonstrating how robotic process automation of selected pharmacovigilance systems can increase efficiency by up to 400 times, increasing speed, reducing cost and improving accuracy. PrimeVigilance is working on the early deployment of robots in its operations. By investing in technology and people, PrimeVigilance has achieved organic growth of around 50% per year over the last few years and has, in addition, successfully incorporated acquired companies. PrimeVigilance aims to be the global leader in pharmacovigilance by 2020.

“PrimeVigilance has consistently demonstrated growth which is in no small part due to our market-leading adoption of new techniques and technologies and we are at the forefront of robotic automation, the next leap forward in technology for our industry. We look forward to discussing these advances in pharmacovigilance automation and how they can increase efficiency and accuracy. Pharmacovigilance is an extremely fast-growing and highly regulated market and we are pleased to be able to share our views on meeting these increasingly complex regulatory requirements.”

Dr Jan Petracek

CEO of PrimeVigilance

For more information on the seminar and to view the full programme, please visit: http://isoponline.org/training/isop-seminar.

 

ENDS

 

 

 

Enquiries:

 

Ergomed plc / PrimeVigilance Limited

Tel: +44 (0) 1483 503205

Jan Petracek (CEO of PrimeVigilance)

 

 

 

 

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

 

James Black (Joint Broker)

 

 

 

N+1 Singer

Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)

 

 

 

Consilium Strategic Communications – for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com

 

 

MC Services – for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

     

 

 

About Ergomed

 

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed’s fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

 


Back to previous page